NEWS | October 27, 2022

Sense Diagnostics Awarded $25,000 Prize at Defense TechConnect (DTC) Innovation Summit & Expo

Cincinnati MedTech Startup one of Eight Winners at 2022 Medical Innovation Challenge
CINCINNATI, OH – October 27, 2022 – Sense Diagnostics was recently recognized as one of seven winners of the 2022 Medical Innovation Challenge at the Defense TechConnect (DTC) Innovation Summit & Expo, the nation’s largest annual gathering of non-traditional, dual-use emerging technologies aligned with government priority requirements.
The seven winners were selected from a field of 25 finalists that presented innovative solutions during the conference’s “Shark Tank”-style pitching. Finalists were given eight minutes to present to industry and government leadership aligned with participating contracting vehicles. An eighth honor recognized a winning student submission and its innovation.
Sense Diagnostics is working to bring to the marketplace a non-invasive technology that enables rapid, comprehensive detection of stroke subtype and traumatic brain injuries as well as continuous brain injury monitoring. Sense’s technology can collect 360 neurological data points in 2.5 seconds and has the potential to help first responders, emergency department personnel, neuro ICU teams, and military field hospitals. The startup currently has several clinical trials underway in the United States, Canada, and India as it works toward commercialization.
Sense Diagnostics Vice President of Research and Development Joseph J. Korfhagen, Ph.D., delivered the winning presentation to a panel of eight judges representing private venture firms and corporations interested in emerging MedTech innovations. “This is a big deal because it allowed a broader audience to learn about Sense’s technology and we’re now exploring some meaningful partnerships,” says Korfhagen. “Once people discover what we’re doing, they see the natural implications of how we can help save lives on the battlefield, as well as help emergency rooms, hospitals, and first responders respond to TBIs and monitor strokes.”
“Besides the natural connection with the Department of Defense, other government connections have reached out about potential collaboration,” says Geoffrey Klass, CEO, Sense Diagnostics. “This was a tremendous opportunity for connecting Sense with additional nondilutive funding and gets us one step closer to saving lives with this technology.”

The Defense TechConnect (DTC) Innovation Summit & Expo is the nation’s largest annual gathering of non-traditional, dual-use emerging technologies aligned with government priority requirements. A unique bridge between private sector innovation, commercialization and government acquisition, DTC accelerates the identification and deployment of novel technologies through rapid access of vetted startups and emerging academic and federal lab innovations.

DTC’s Medical Innovation Challenge is aligned with four MedTech consortia representing more than $20 billion in health technology contracting authority: Medical CBRN Defense Consortium (MCDC), Countering Weapons of Mass Destruction Consortium (CWMD), Medical Technology Enterprise Consortium (MTEC), Senior Healthcare Innovation Consortium (SHIC). This year’s challenge featured several areas of interest, including devices and sensors, digital and hardware, therapeutics and treatments, materials and manufacturing, and readiness and response.

About Sense Diagnostics
Sense Diagnostics is focused on improving outcomes for stroke and brain injury patients through technology innovations that enable faster detection and more effective triage. Sense is developing non-invasive technology to enable continuous, real-time brain injury monitoring as well as rapid detection of traumatic brain injury and important stroke subtypes. Learn about the ongoing pivotal trial for continuous monitoring of intracranial hemorrhage, and successful first-in-human pilot study of triage technology to determine stroke subtype at